Vorinostat enhances cytotoxicity of SN-38 and temozolomide in ewing sarcoma cells and activates STAT3/AKT/MAPK pathways

PLoS ONE

Volumn 10, Issue 11, 2015, Pages

  Sampson, Valerie B ^a   Vetter, Nancy S ^a   Kamara, Davida F ^a   Collier, Anderson B ^b   Gresh, Renee C ^a   Kolb, E Anders ^a  

^a NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

^b UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; FIRTECAN; HISTONE H2B; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; SOMATOMEDIN C RECEPTOR; STAT3 PROTEIN; TEMOZOLOMIDE; VORINOSTAT; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CASPASE 3; DACARBAZINE; FUSED HETEROCYCLIC RINGS; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; IRINOTECAN; PROTEIN P53;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL CYCLE G0 PHASE; CELL VIABILITY; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG POTENCY; DRUG POTENTIATION; DRUG SCREENING; EWING SARCOMA; EWING SARCOMA CELL LINE; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; PROTEIN ACETYLATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; ACETYLATION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECTS; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ACETYLATION; ANTINEOPLASTIC AGENTS; APOPTOSIS; CAMPTOTHECIN; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DACARBAZINE; DNA DAMAGE; G1 PHASE CELL CYCLE CHECKPOINTS; HETEROCYCLIC COMPOUNDS, 3-RING; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; MITOGEN-ACTIVATED PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; REACTIVE OXYGEN SPECIES; SARCOMA, EWING; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84957111295     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0142704     Document Type: Article

References (51)

1. Arndt CA, Rose PS, Folpe AL, Laack NN. Common musculoskeletal tumors of childhood and adolescence. Mayo Clin Proc. 2012; 87(5):475-87. Epub 2012/05/09. doi: S0025-6196(12)00301-1 [pii] doi: 10.1016/j.mayocp.2012.01.015 PMID: 22560526.
2. Ferrari S, Palmerini E, Alberghini M, Staals E, Mercuri M, Barbieri E, et al. Vincristine, doxorubicin, cyclophosfamide, actinomycin D, ifosfamide, and etoposide in adult and pediatric patients with nonmetastatic Ewing sarcoma. Final results of a monoinstitutional study. Tumori. 2010; 96(2):213-8. Epub 2010/06/25. PMID: 20572576.
3. Duchman KR, Gao Y, Miller BJ. Prognostic factors for survival in patients with Ewing's sarcoma using the surveillance, epidemiology, and end results (SEER) program database. Cancer Epidemiol. 2015; 39(2):189-95. Epub 2015/01/18. doi: S1877-7821(14)00231-8 [pii] doi: 10.1016/j.canep.2014.12.012 PMID: 25595632.
4. Hawkins DS. Sarcomas gone bad: what to do about recurrent Ewing sarcoma. Pediatr Blood Cancer. 2011; 57(4):535-6. Epub 2011/06/18. doi: 10.1002/pbc.23126 PMID: 21681926.
5. Tosso PN, Kong Y, Scher L, Cummins R, Schneider J, Rahim S, et al. Synthesis and structure-activity relationship studies of small molecule disruptors of EWS-FLI1 interactions in Ewing's sarcoma. J Med Chem. 2014; 57(24):10290-303. Epub 2014/11/29. doi: 10.1021/jm501372p PMID: 25432018.
6. Kolb EA, Gorlick R, Maris JM, Keir ST, Morton CL, Wu J, et al. Combination testing (Stage 2) of the Anti-IGF-1 receptor antibody IMC-A12 with rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer. 2012; 58(5):729-35. Epub 2011/06/02. doi: 10.1002/pbc.23157 PMID: 21630428.
7. Kurmasheva RT, Dudkin L, Billups C, Debelenko LV, Morton CL, Houghton PJ. The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma. Cancer Res. 2009; 69(19):7662-71. Epub 2009/10/01.doi: 0008-5472.CAN-09-1693 [pii] doi: 10.1158/0008-5472.CAN-09-1693 PMID: 19789339.
8. Sampson VB, Gorlick R, Kamara D, Anders Kolb E. A review of targeted therapies evaluated by the pediatric preclinical testing program for osteosarcoma. Front Oncol. 2013; 3:132. Epub 2013/06/12. doi: 10.3389/fonc.2013.00132 PMID: 23755370.
9. Spiller SE, Ravanpay AC, Hahn AW, Olson JM. Suberoylanilide hydroxamic acid is effective in preclinical studies of medulloblastoma. J Neurooncol. 2006; 79(3):259-70. Epub 2006/04/29. doi: 10.1007/s11060-006-9142-0 PMID: 16645722.
10. Keshelava N, Houghton PJ, Morton CL, Lock RB, Carol H, Keir ST, et al. Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program. Pediatr Blood Cancer. 2009; 53(3):505-8. doi: 10.1002/pbc.21988 PMID: 19418547; PubMed Central PMCID: PMCPMC2752378.
11. Bevins RL, Zimmer SG. It's about time: scheduling alters effect of histone deacetylase inhibitors on camptothecin-treated cells. Cancer Res. 2005; 65(15):6957-66. Epub 2005/08/03. doi: 65/15/6957 [pii] doi: 10.1158/0008-5472.CAN-05-0836 PMID: 16061681.
12. Gray J, Cubitt CL, Zhang S, Chiappori A. Combination of HDAC and topoisomerase inhibitors in small cell lung cancer. Cancer Biol Ther. 2012; 13(8):614-22. Epub 2012/03/24. doi: 19848 [pii] doi: 10.4161/cbt.19848 PMID: 22441819.
13. Chibbaro S, Benvenuti L, Caprio A, Carnesecchi S, Pulera F, Faggionato F, et al. Temozolomide as first-line agent in treating high-grade gliomas: phase II study. J Neurooncol. 2004; 67(1-2):77-81. Epub 2004/04/10. PMID: 15072451.
14. Abrey LE, Olson JD, Raizer JJ, Mack M, Rodavitch A, Boutros DY, et al. A phase II trial of temozolomide for patients with recurrent or progressive brain metastases. J Neurooncol. 2001; 53(3):259-65. Epub 2001/11/23. PMID: 11718258.
15. Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol. 1999; 17(9):2762-71. Epub 1999/11/24. PMID: 10561351.
16. Hummel TR, Wagner L, Ahern C, Fouladi M, Reid JM, McGovern RM, et al. A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study. Pediatr Blood Cancer. 2013; 60(9):1452-7. Epub 2013/04/05. doi: 10.1002/pbc.24541 PMID: 23554030.
17. Mullins CD, Hsiao FY, Onukwugha E, Pandya NB, Hanna N. Comparative and cost-effectiveness of oxaliplatin-based or irinotecan-based regimens compared with 5-fluorouracil/leucovorin alone among US elderly stage IV colon cancer patients. Cancer. 2012; 118(12):3173-81. Epub 2011/10/25. doi: 10. 1002/cncr.26613 PMID: 22020739.
18. Wagner LM, McAllister N, Goldsby RE, Rausen AR, McNall-Knapp RY, McCarville MB, et al. Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma. Pediatr Blood Cancer. 2007; 48(2):132-9. Epub 2005/12/01. doi: 10.1002/pbc.20697 PMID: 16317751.
19. Casey DA, Wexler LH, Merchant MS, Chou AJ, Merola PR, Price AP, et al. Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience. Pediatr Blood Cancer. 2009; 53 (6):1029-34. Epub 2009/07/29. doi: 10.1002/pbc.22206 PMID: 19637327.
20. Mirzayans R, Andrais B, Scott A, Murray D. New insights into p53 signaling and cancer cell response to DNA damage: implications for cancer therapy. J Biomed Biotechnol. 2012; 2012:170325. Epub 2012/08/23. doi: 10.1155/2012/170325 PMID: 22911014.
21. Osuna D, de Alava E. Molecular pathology of sarcomas. Rev Recent Clin Trials. 2009; 4(1):12-26. Epub 2009/01/20. PMID: 19149759.
22. Kolb EA, Kamara D, Zhang W, Lin J, Hingorani P, Baker L, et al. R1507, a fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts. Pediatr Blood Cancer. 2010; 55(1):67-75. Epub 2010/05/21. doi: 10.1002/pbc. 22479 PMID: 20486173.
23. Sarcar B, Kahali S, Chinnaiyan P. Vorinostat enhances the cytotoxic effects of the topoisomerase I inhibitor SN38 in glioblastoma cell lines. J Neurooncol. 2010; 99(2):201-7. Epub 2010/02/06. doi: 10. 1007/s11060-010-0127-7 PMID: 20135194.
24. Erkizan HV, Scher LJ, Gamble SE, Barber-Rotenberg JS, Sajwan KP, Uren A, et al. Novel peptide binds EWS-FLI1 and reduces the oncogenic potential in Ewing tumors. Cell Cycle. 2011; 10(19):3397-408. doi: 10.4161/cc.10.19.17734 PMID: 21926473; PubMed Central PMCID: PMCPMC3233630.
25. Sharifi S, Barar J, Hejazi MS, Samadi N. Doxorubicin Changes Bax/Bcl-xL Ratio, Caspase-8 and 9 in Breast Cancer Cells. Adv Pharm Bull. 2015; 5(3):351-9. doi: 10.15171/apb.2015.049 PMID: 26504757.
26. Goodarzi AA, Jeggo P, Lobrich M. The influence of heterochromatin on DNA double strand break repair: Getting the strong, silent type to relax. DNA Repair (Amst). 2010; 9(12):1273-82. Epub 2010/11/03. doi: S1568-7864(10)00318-6 [pii] doi: 10.1016/j.dnarep.2010.09.013 PMID: 21036673.
27. Caporali S, Falcinelli S, Starace G, Russo MT, Bonmassar E, Jiricny J, et al. DNA damage induced by temozolomide signals to both ATM and ATR: role of the mismatch repair system. Mol Pharmacol. 2004; 66(3):478-91.PMID: 15322239.
28. Naumann SC, Roos WP, Jost E, Belohlavek C, Lennerz V, Schmidt CW, et al. Temozolomide-and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53. Br J Cancer. 2009; 100(2):322-33. doi: 10.1038/sj.bjc.6604856 PMID: 19127257; PubMed Central PMCID: PMCPMC2634706.
29. Roos WP, Batista LF, Naumann SC, Wick W, Weller M, Menck CF, et al. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. Oncogene. 2007; 26 (2):186-97. doi: 10.1038/sj.onc.1209785 PMID: 16819506.
30. Thurow HS, Hartwig FP, Alho CS, Silva DS, Roesler R, Abujamra AL, et al. Ewing Sarcoma: influence of TP53 Arg72Pro and MDM2 T309G SNPs. Mol Biol Rep. 2013; 40(8):4929-34. Epub 2013/05/11. doi: 10.1007/s11033-013-2593-4 PMID: 23661019.
31. May WA, Grigoryan RS, Keshelava N, Cabral DJ, Christensen LL, Jenabi J, et al. Characterization and drug resistance patterns of Ewing's sarcoma family tumor cell lines. PLoS One. 2013; 8(12):e80060. doi: 10.1371/journal.pone.0080060 PMID: 24312454; PubMed Central PMCID: PMCPMC3846563.
32. Guerzoni C, Fiori V, Terracciano M, Manara MC, Moricoli D, Pasello M, et al. CD99 triggering in Ewing sarcoma delivers a lethal signal through p53 pathway reactivation and cooperates with doxorubicin. Clin Cancer Res. 2015; 21(1):146-56. doi: 10.1158/1078-0432.CCR-14-0492 PMID: 25501132.
33. Pishas KI, Adwal A, Neuhaus SJ, Clayer MT, Farshid G, Staudacher AH, et al. XI-006 induces potent p53-independent apoptosis in Ewing sarcoma. Sci Rep. 2015; 5:11465. doi: 10.1038/srep11465 PMID: 26095524; PubMed Central PMCID: PMCPMC4476092.
34. Grohar PJ, Woldemichael GM, Griffin LB, Mendoza A, Chen QR, Yeung C, et al. Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening. J Natl Cancer Inst. 2011; 103(12):962-78. doi: 10.1093/jnci/djr156 PMID: 21653923; PubMed Central PMCID: PMCPMC3119649.
35. Lu C, Tilan JU, Everhart L, Czarnecka M, Soldin SJ, Mendu DR, et al. Dipeptidyl peptidases as survival factors in Ewing sarcoma family of tumors: implications for tumor biology and therapy. J Biol Chem. 2011; 286(31):27494-505. doi: 10.1074/jbc.M111.224089 PMID: 21680731; PubMed Central PMCID: PMCPMC3149342.
36. Juengel E, Makarevic J, Tsaur I, Bartsch G, Nelson K, Haferkamp A, et al. Resistance after chronic application of the HDAC-inhibitor valproic acid is associated with elevated Akt activation in renal cell carcinoma in vivo. PLoS One. 2013; 8(1):e53100. Epub 2013/02/02. doi: 10.1371/journal.pone. 0053100 PONE-D-12-25060 [pii]. PMID: 23372654.
37. Kitange GJ, Mladek AC, Carlson BL, Schroeder MA, Pokorny JL, Cen L, et al. Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts. Clin Cancer Res. 2012; 18(15):4070-9. Epub 2012/06/08. doi: 1078-0432. CCR-12-0560 [pii] doi: 10.1158/1078-0432.CCR-12-0560 PMID: 22675172.
38. Subbiah V, Naing A, Brown RE, Chen H, Doyle L, LoRusso P, et al. Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signatures. PLoS One. 2011; 6(4):e18424. Epub 2011/04/16. doi: 10.1371/journal.pone. 0018424 PMID: 21494688.
39. Sampson VB, Gorlick R, Kamara D, Kolb E. A review of targeted therapies evaluated by the pediatric preclinical testing program for osteosarcoma. Front Oncol. 2013; 3:132. Epub 2013/06/12. doi: 10. 3389/fonc.2013.00132 PMID: 23755370.
40. Kim JS, Kim ES, Liu D, Lee JJ, Behrens C, Lippman SM, et al. Activation of insulin-like growth factor 1 receptor in patients with non-small cell lung cancer. Oncotarget. 2015; 6(18):16746-56. Epub 2015/05/07. doi: 3796 [pii]. PMID: 25944691.
41. Niemeyer BF, Parrish JK, Spoelstra NS, Joyal T, Richer JK, Jedlicka P. Variable expression of PIK3R3 and PTEN in Ewing Sarcoma impacts oncogenic phenotypes. PLoS One. 2015; 10(1):e0116895. doi: 10.1371/journal.pone.0116895 PMID: 25603314; PubMed Central PMCID: PMCPMC4300218.
42. Stewart E, Goshorn R, Bradley C, Griffiths LM, Benavente C, Twarog NR, et al. Targeting the DNA repair pathway in Ewing sarcoma. Cell Rep. 2014; 9(3):829-41. Epub 2014/12/02. doi: S2211-1247 (14)00811-0 [pii] doi: 10.1016/j.celrep.2014.09.028 PMID: 25437539.
43. Garcia-Manero G, Yang H, Bueso-Ramos C, Ferrajoli A, Cortes J, Wierda WG, et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood. 2008; 111(3):1060-6. Epub 2007/10/27. doi: blood-2007-06-098061 [pii] doi: 10.1182/blood-2007-06-098061 PMID: 17962510.
44. Daud AI, Dawson J, DeConti RC, Bicaku E, Marchion D, Bastien S, et al. Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial. Clin Cancer Res. 2009; 15(7):2479-87. Epub 2009/03/26. doi: 1078-0432. CCR-08-1931 [pii] doi: 10.1158/1078-0432.CCR-08-1931 PMID: 19318485.
45. Ban J, Bennani-Baiti IM, Kauer M, Schaefer KL, Poremba C, Jug G, et al. EWS-FLI1 suppresses NOTCH-activated p53 in Ewing's sarcoma. Cancer Res. 2008; 68(17):7100-9. doi: 10.1158/0008-5472.CAN-07-6145 PMID: 18757425.
46. Cordenonsi M, Montagner M, Adorno M, Zacchigna L, Martello G, Mamidi A, et al. Integration of TGFbeta and Ras/MAPK signaling through p53 phosphorylation. Science. 2007; 315(5813):840-3. Epub 2007/01/20. doi: 1135961 [pii] doi: 10.1126/science.1135961 PMID: 17234915.
47. Huang C, Ma WY, Goranson A, Dong Z. Resveratrol suppresses cell transformation and induces apoptosis through a p53-dependent pathway. Carcinogenesis. 1999; 20(2):237-42. Epub 1999/03/09. PMID: 10069459.
48. Singh RP, Dhawan P, Golden C, Kapoor GS, Mehta KD. One-way cross-talk between p38(MAPK) and p42/44(MAPK). Inhibition of p38(MAPK) induces low density lipoprotein receptor expression through activation of the p42/44(MAPK) cascade. J Biol Chem. 1999; 274(28):19593-600. Epub 1999/07/03. PMID: 10391894.
49. McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, et al. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul. 2006; 46:249-79. Epub 2006/07/21. doi: S0065-2571(06)00003-3 [pii] doi: 10.1016/j. advenzreg.2006.01.004 PMID: 16854453.
50. Lerman DM, Monument MJ, McIlvaine E, Liu XQ, Huang D, Monovich L, et al. Tumoral TP53 and/or CDKN2A alterations are not reliable prognostic biomarkers in patients with localized Ewing sarcoma: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2015; 62(5):759-65. doi: 10.1002/pbc.25340 PMID: 25464386; PubMed Central PMCID: PMCPMC4376595.
51. Lee ER, Kim JY, Kang YJ, Ahn JY, Kim JH, Kim BW, et al. Interplay between PI3K/Akt and MAPK signaling pathways in DNA-damaging drug-induced apoptosis. Biochim Biophys Acta. 2006; 1763 (9):958-68. doi: 10.1016/j.bbamcr.2006.06.006 PMID: 16905201.